Asembia Specialty Pharmacy Summit
Asembia Specialty Pharmacy Summit
We’re looking forward to engaging with industry leaders in person at AXS24. Our cross-functional experts will be available to discuss the following topics:
May 1st 3–3:45 PM PT
ICER’s Influence on IRA, Pricing, and Value: Student or Teacher?
Laura Housman, Mike Ciarametaro, Jordan Banks and Taylor Schwartz
Priority Topics
Navigating Launch and Commercialization:
Manufacturers need a strategic pre-commercial plan for pipeline assets, starting with the clinical impact of products in development. This plan should address the pharmacoeconomic value, access, and health policy considerations that influence market success. Avalere is rooted in a team of trusted experts whose experiences span each segment of the healthcare ecosystem. This experience, combined with data and analytics, is designed to provide a 360° view critical to pre-launch activities including TPP characterization, competitive landscape analysis, evidence planning, asset valuation and forecasting, value proposition development and testing, and launch execution.
Lessons From Year 1 of Medicare Drug Price Negotiation Program:
Precedents set in the first year of the Medicare Drug Price Negotiation Program offer key insights into CMS’s priorities and policies, operational challenges, and downstream access risk. This information can be used to shape future strategy impacting manufacturers, plans and patients. Avalere experts support clients optimizing their positioning, from evidence submissions to pricing and contracting, and lessons about the impact on customer stakeholders (e.g., specialty pharmacies, PBMs, commercial plans, etc.).
Part D Strategy and Bid Modeling:
Manufacturers can expect Part D volume and revenue changes and should prepare for new plan approaches to formulary and benefit design. As 2025 contracting comes to an end, manufacturers should be prepared for 2026 contracting strategy. Avalere can be a thought partner to manufacturers developing their strategy for engaging Part D plans using qualitative and quantitative approaches to demonstrate value.
Evolving Definition of Economic Value for New Therapies:
Recent policies in US and ex-US markets (i.e., Joint Clinical Assessment, Inflation Reduction Act, FDA Data Requirements), evolving stakeholder expectations, and enhanced focus on sustained access have intensified requirements for demonstrating value. Avalere’s multitude of experts support clients in crafting a holistic value proposition that not only considers the long-term value for money and short-term affordability, but also accounts for health equity, enhanced societal impact, and opining on CMSs’ Inflation Reduction Act negotiations.
Meet Our
Experts
The Avalere experts below will attend Asembia’s 2024 Specialty Pharmacy Summit. Connect with them and see how Avalere can help your business.
Taylor Schwartz
Omar Hafez
Michael Ciarametaro
Mark Gooding
Laura Housman
Jordan Banks
John C. Neal
Clay Keene
Meet us at Asembia
Read Our Take on Top Trends
Specialty Pharmacies Adapt to Support Cell and Gene Therapies
Specialty pharmacies are evolving to support the unique distribution requirements of CGTs and the co...
IRA Negotiation Creates Ripple Effects Across Drug Markets
Medicare negotiation has ripple effects across therapeutic markets, requiring manufacturers to reass...
Featured Services
Market Access and Commercialization
Helping life sciences companies successfully initiate and sustain product commercialization at each point along the access-and-commercialization continuum.
Health Economics and Outcomes Research (HEOR)
Using our comprehensive real-world data access to develop real-world evidence that supports data-driven decision making and market differentiation.
Federal and State Policy
Providing clients with multistakeholder perspectives to help them anticipate, interpret, and respond to changes in the complex legislative and regulatory environment.